Literature DB >> 9930743

Decreased brain protein levels of cytochrome oxidase subunits in Alzheimer's disease and in hereditary spinocerebellar ataxia disorders: a nonspecific change?

S J Kish1, F Mastrogiacomo, M Guttman, Y Furukawa, J W Taanman, S Dozić, M Pandolfo, J Lamarche, L DiStefano, L J Chang.   

Abstract

Controversy exists as to the clinical importance, cause, and disease specificity of the cytochrome oxidase (CO) activity reduction observed in some patients with Alzheimer's disease (AD). Although it is assumed that the enzyme is present in normal amount in AD, no direct measurements of specific CO protein subunits have been conducted. We measured protein levels of CO subunits encoded by mitochondrial (COX I, COX II) and nuclear (COX IV, COX VIc) DNA in autopsied brain of patients with AD whom we previously reported had decreased cerebral cortical CO activity. To assess disease specificity, groups of patients with spinocerebellar ataxia type I and Friedreich's ataxia were also included. As compared with the controls, mean protein concentrations of all four CO subunits were significantly decreased (-19 to -47%) in temporal and parietal cortices in the AD group but were not significantly reduced (-12 to -17%) in occipital cortex. The magnitude of the reduction in protein levels of the CO subunits encoded by mitochondrial DNA (-42 to -47%) generally exceeded that encoded by nuclear DNA (-19 to -43%). In the spinocerebellar ataxia disorders, COX I and COX II levels were significantly decreased in cerebellar cortex (-22 to -32%) but were normal or close to normal in cerebral cortex, an area relatively unaffected by neurodegeneration. We conclude that protein levels of mitochondrial- and nuclear-encoded CO subunits are moderately reduced in degenerating but not in relatively spared brain areas in AD and that the decrease is not specific to this disorder. The simplest explanation for our findings is that CO is decreased in human brain disorders as a secondary event in brain areas having reduced neuronal activity or neuronal/synaptic elements consequent to the primary neurodegenerative process.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9930743     DOI: 10.1046/j.1471-4159.1999.0720700.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  30 in total

Review 1.  Amyloid-beta-induced mitochondrial dysfunction.

Authors:  John Xi Chen; Shi Du Yan
Journal:  J Alzheimers Dis       Date:  2007-09       Impact factor: 4.472

Review 2.  Multivariate meta-analyses of mitochondrial complex I and IV in major depressive disorder, bipolar disorder, schizophrenia, Alzheimer disease, and Parkinson disease.

Authors:  L Holper; D Ben-Shachar; J J Mann
Journal:  Neuropsychopharmacology       Date:  2018-05-16       Impact factor: 7.853

Review 3.  The neurodegenerative mitochondriopathies.

Authors:  Russell H Swerdlow
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

Review 4.  Amyloid precursor protein-mediated mitochondrial regulation and Alzheimer's disease.

Authors:  M Isabel G Lopez Sanchez; Peter van Wijngaarden; Ian A Trounce
Journal:  Br J Pharmacol       Date:  2018-12-18       Impact factor: 8.739

5.  Prospects for redox-based therapy in neurodegenerative diseases.

Authors:  A L Friedlich; M F Beal
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

Review 6.  Mitochondria, OxPhos, and neurodegeneration: cells are not just running out of gas.

Authors:  Estela Area-Gomez; Cristina Guardia-Laguarta; Eric A Schon; Serge Przedborski
Journal:  J Clin Invest       Date:  2019-01-02       Impact factor: 14.808

Review 7.  Mitochondrial Dysfunction and Synaptic Transmission Failure in Alzheimer's Disease.

Authors:  Lan Guo; Jing Tian; Heng Du
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

8.  Beta-amyloid mediated nitration of manganese superoxide dismutase: implication for oxidative stress in a APPNLH/NLH X PS-1P264L/P264L double knock-in mouse model of Alzheimer's disease.

Authors:  Muthuswamy Anantharaman; Jitbanjong Tangpong; Jeffery N Keller; Michael P Murphy; William R Markesbery; Kelley K Kiningham; Daret K St Clair
Journal:  Am J Pathol       Date:  2006-05       Impact factor: 4.307

Review 9.  Mitochondrial abnormalities in Alzheimer's disease: possible targets for therapeutic intervention.

Authors:  Diana F Silva; J Eva Selfridge; Jianghua Lu; Lezi E; Sandra M Cardoso; Russell H Swerdlow
Journal:  Adv Pharmacol       Date:  2012

10.  Alzheimer's brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication.

Authors:  Pinar E Coskun; M Flint Beal; Douglas C Wallace
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.